HLB Co., Ltd. (KOSDAQ:028300)
South Korea · Delayed Price · Currency is KRW 31,450
-200 (-0.63%)
Sep 11, 2026, 3:30 PM KST
HLB Co., Ltd. Revenue
HLB Co., Ltd. had revenue of 28.00B KRW in the quarter ending June 30, 2026, with 77.99% growth. This brings the company's revenue in the last twelve months to 97.47B, up 28.97% year-over-year. In the year 2025, HLB Co., Ltd. had annual revenue of 84.17B with 23.55% growth.
Revenue (ttm)
97.47B
Revenue Growth
+28.97%
P/S Ratio
42.90
Revenue / Employee
649.78M
Employees
150
Market Cap
4.18T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 84.17B | 16.05B | 23.55% |
| Dec 31, 2024 | 68.13B | 25.23B | 58.80% |
| Dec 31, 2023 | 42.90B | -136.81B | -76.13% |
| Dec 31, 2022 | 179.71B | 109.88B | 157.37% |
| Dec 31, 2021 | 69.83B | 13.65B | 24.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Epis Holdings | 1.51T |
| SK Biopharmaceuticals | 861.34B |
| SK bioscience | 659.27B |
| Hugel | 479.57B |
| LigaChem Biosciences | 98.78B |
| ABL Bio | 34.28B |
| OliX Pharmaceuticals | 13.64B |
| Peptron | 6.00B |
HLB Co., Ltd. News
- 4 weeks ago - HLB Co., Ltd. Quarterly report: Q2 2026 - Filings
- 4 months ago - HLB Co., Ltd. Quarterly report: Q1 2026 - Filings
- 5 months ago - HLB Co., Ltd. Annual report: Q4 2025 - Filings
- 10 months ago - HLB Co., Ltd. Quarterly report: Q3 2025 - Filings